Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
MIRUM PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
604749101
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 604749101
| (1) | Names of reporting persons Takeda Pharmaceutical Company Limited | |||||||||||||||||||||||||||||||||||||
| (2) | Check the appropriate box if a member of a group (see instructions) (a) ☐ (b) ☐ | |||||||||||||||||||||||||||||||||||||
| (3) | SEC use only | |||||||||||||||||||||||||||||||||||||
| (4) | Citizenship or place of organization Japan | |||||||||||||||||||||||||||||||||||||
Number of shares beneficially owned by each reporting person with: | (5) | Sole voting power 0 | ||||||||||||||||||||||||||||||||||||
| (6) | Shared voting power 1,859,151 | |||||||||||||||||||||||||||||||||||||
| (7) | Sole dispositive power 0 | |||||||||||||||||||||||||||||||||||||
| (8) | Shared dispositive power 1,859,151 | |||||||||||||||||||||||||||||||||||||
| (9) | Aggregate amount beneficially owned by each reporting person 1,859,151 (1) | |||||||||||||||||||||||||||||||||||||
| (10) | Check if the aggregate amount in Row (9) excludes certain shares (see instructions) ☐ | |||||||||||||||||||||||||||||||||||||
| (11) | Percent of class represented by amount in Row (9) 7.2% (2) | |||||||||||||||||||||||||||||||||||||
| (12) | Type of reporting person (see instructions) CO | |||||||||||||||||||||||||||||||||||||
(1) Takeda Pharmaceutical Company Limited’s beneficial ownership of the issuer’s Common Stock is comprised of 1,859,151 shares of Common Stock held by Takeda Pharmaceuticals U.S.A., Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (70.9%), Takeda Pharmaceuticals International AG (27.3%), and Shire Ireland Investment Ltd. (1.8%). Each of Shire Ireland Investment Ltd. and Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
(2) Based on 25,716,877 shares of Common Stock outstanding as of November 6, 2020, as disclosed in the issuer’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2020 filed with the SEC on November 12, 2020 (“10-Q”).
Page 2 of 7 pages
CUSIP No. 604749101
| (1) | Names of reporting persons Takeda Pharmaceuticals U.S.A., Inc. | |||||||||||||||||||||||||||||||||||||
| (2) | Check the appropriate box if a member of a group (see instructions) (a) ☐ (b) ☐ | |||||||||||||||||||||||||||||||||||||
| (3) | SEC use only | |||||||||||||||||||||||||||||||||||||
| (4) | Citizenship or place of organization United States of America | |||||||||||||||||||||||||||||||||||||
Number of shares beneficially owned by each reporting person with: | (5) | Sole voting power 0 | ||||||||||||||||||||||||||||||||||||
| (6) | Shared voting power 1,859,151 | |||||||||||||||||||||||||||||||||||||
| (7) | Sole dispositive power 0 | |||||||||||||||||||||||||||||||||||||
| (8) | Shared dispositive power 1,859,151 | |||||||||||||||||||||||||||||||||||||
| (9) | Aggregate amount beneficially owned by each reporting person 1,859,151 | |||||||||||||||||||||||||||||||||||||
| (10) | Check if the aggregate amount in Row (9) excludes certain shares (see instructions) ☐ | |||||||||||||||||||||||||||||||||||||
| (11) | Percent of class represented by amount in Row (9) 7.2% (1) | |||||||||||||||||||||||||||||||||||||
| (12) | Type of reporting person (see instructions) CO | |||||||||||||||||||||||||||||||||||||
(1) Based on 25,716,877 shares of Common Stock outstanding as of November 6, 2020, as disclosed in the issuer’s 10-Q.
Page 3 of 7 pages
| (1) | Names of reporting persons Shire International GmbH in Liquidation (1) | |||||||||||||||||||||||||||||||||||||
| (2) | Check the appropriate box if a member of a group (see instructions) (a) ☐ (b) ☐ | |||||||||||||||||||||||||||||||||||||
| (3) | SEC use only | |||||||||||||||||||||||||||||||||||||
| (4) | Citizenship or place of organization Switzerland | |||||||||||||||||||||||||||||||||||||
Number of shares beneficially owned by each reporting person with: | (5) | Sole voting power 0 | ||||||||||||||||||||||||||||||||||||
| (6) | Shared voting power 0 | |||||||||||||||||||||||||||||||||||||
| (7) | Sole dispositive power 0 | |||||||||||||||||||||||||||||||||||||
| (8) | Shared dispositive power 0 | |||||||||||||||||||||||||||||||||||||
| (9) | Aggregate amount beneficially owned by each reporting person 0 | |||||||||||||||||||||||||||||||||||||
| (10) | Check if the aggregate amount in Row (9) excludes certain shares (see instructions) ☐ | |||||||||||||||||||||||||||||||||||||
| (11) | Percent of class represented by amount in Row (9) 0% (2) | |||||||||||||||||||||||||||||||||||||
| (12) | Type of reporting person (see instructions) CO | |||||||||||||||||||||||||||||||||||||
(1) Pursuant to a corporate restructuring, Shire International GmbH in Liquidation, which is a direct wholly owned subsidiary of Shire Pharmaceuticals International UC, which is a direct wholly owned subsidiary of Shire Human Genetic Therapies, Inc., which is a direct wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc., transferred to Takeda Pharmaceuticals U.S.A., Inc., all of the Common Stock of the issuer previously directly held of record by Shire International GmbH in Liquidation.
(2) Based on 25,716,877 shares of Common Stock outstanding as of November 6, 2020, as disclosed in the issuer’s 10-Q.
Page 4 of 7 pages
Item 1(a) Name of issuer:
Mirum Pharmaceuticals, Inc.
Item 1(b) Address of issuer’s principal executive offices:
950 Tower Lane, Suite 1050, Foster City, California 94404
Item 2(a) Name of person filing:
Takeda Pharmaceutical Company Limited
Takeda Pharmaceuticals U.S.A., Inc.
Shire International GmbH in Liquidation
Item 2(b) Address of principal business office or, if none, residence:
Takeda Pharmaceutical Company Limited – 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan
Takeda Pharmaceuticals U.S.A., Inc. – 95 Hayden Avenue, Lexington, MA 02421 United States of America
Shire International GmbH in Liquidation – Thurgauerstrasse 130, 8152 Glattpark (Opfikon), Switzerland
Item 2(c) Citizenship:
Takeda Pharmaceutical Company Limited – Japan
Takeda Pharmaceuticals U.S.A., Inc. – Delaware, United States of America
Shire International GmbH in Liquidation – Switzerland
Item 2(d) Title of class of securities:
Common Stock, par value $0.0001 per share
Item 2(e) CUSIP No.:
604749101
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable.
Item 4. Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: See the responses to Item 9 on the attached cover pages.
(b) Percent of class: See the responses to Item 11 on the attached cover pages.
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: See the responses to Item 5 on the attached cover pages.
(ii) Shared power to vote or to direct the vote: See the responses to Item 6 on the attached cover pages.
(iii) Sole power to dispose or to direct the disposition of: See the responses to Item 7 on the attached cover pages.
Page 5 of 7 pages
(iv) Shared power to dispose or to direct the disposition of: See the responses to Item 8 on the attached cover pages.
Item 5. Ownership of 5 Percent or Less of a Class.
Pursuant to a corporate restructuring, Shire International GmbH in Liquidation, which is a direct wholly owned subsidiary of Shire Pharmaceuticals International UC, which is a direct wholly owned subsidiary of Shire Human Genetic Therapies, Inc., which is a direct wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc., transferred to Takeda Pharmaceuticals U.S.A., Inc., all of the Common Stock of the issuer previously directly held of record by Shire International GmbH in Liquidation. Shire International GmbH in Liquidation does not beneficially own directly or indirectly any Common Stock of the issuer and has ceased to be the beneficial owner of more than five percent the issuer’s Common Stock.
Item 6. Ownership of More than 5 Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
See Exhibit 99.1.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Page 6 of 7 pages
Signatures
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: January 27, 2021
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | ||||||||
| By | /s/ Yoshihiro Nakagawa | |||||||
| Name: | Yoshihiro Nakagawa | |||||||
| Title: | Corporate Officer, Global General Counsel | |||||||
TAKEDA PHARMACEUTICALS U.S.A, INC. | ||||||||
| By | /s/ Paul Sundberg | |||||||
| Name: | Paul Sundberg | |||||||
| Title: | Assistant Secretary | |||||||
SHIRE INTERNATIONAL GMBH IN LIQUIDATION | ||||||||
| By | /s/ Barbara Lenzlinger | |||||||
| Name: | Barbara Lenzlinger | |||||||
| Title: | Liquidator | |||||||
Page 7 of 7 pages
INDEX TO EXHIBITS
<
font>
Exhibit 99.1 | |||||
Exhibit 99.2 | |||||